Abstract:Abstract Mutations that occur within the oligomerization domain (OD) of the tumor suppressor p53 generally abolish p53 tetramerization and are associated with increased cancer susceptibility in Li-Fraumeni syndrome (LFS). Despite their prevalence, the impact of OD-mutant p53 proteins in cancer, especially beyond a loss of canonical p53 activity, has not been well elucidated. We sought to delineate the gain-of-function (GOF) vs. loss-of-function (LOF) activities of OD-mutant p53, specifically focusing on the LFS tumor-derived p53(A347D) variant. We obtained LFS patient-derived dermal fibroblasts heterozygous for the mutation and generated an allelic series of U2OS cancer cell lines expressing wild-type p53, heterozygous (p53+/AD) or homozygous (p53AD/AD) mutant p53 or no p53 (p53 KO). In contrast to wild-type p53, mutant p53(A347D) exclusively forms dimers in both fibroblasts and cancer cells and has lost the ability to bind and transactivate the majority of canonical p53 target genes, which yields comparable tumorigenic properties between mutant p53 and p53 KO cells. Mutant p53(A347D), however, displays neomorphic activities. Glycolysis and oxidative phosphorylation pathways are enriched in cells bearing p53(A347D) relative to both wild-type p53 and p53 KO cells. Furthermore, dimeric mutant p53 induces striking mitochondrial network aberration and preferentially associates with mitochondria to drive apoptotic cell death upon topoisomerase II inhibition in the absence of transcription. Ultimately, we describe dimeric mutant p53 as wielding a double-edged sword: driving tumorigenesis through LOF while gaining enhanced apoptogenic activity, thereby providing a potential basis for select therapeutic approaches. Citation Format: Joshua H. Choe, Tatsuya Kawase, An Xu, Asja Guzman, David R. Tong, Aleksandar Z. Obradovic, Ana M. Low-Calle, Bita Alaghebandan, Ananya Raghavan, Kaitlin Long, Paul M. Hwang, Joshua D. Schiffman, Yan Zhu, Ruiying Zhao, Dung-Fang Lee, Chen Katz, Carol L. Prives. Li-Fraumeni syndrome-associated dimer-forming mutant p53 promotes transactivation-independent mitochondrial cell death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr LB361.

Multiscale simulations reveal the driving forces of p53C phase separation accelerated by oncogenic mutations

Phase separation of p53 induced by its unstructured basic region and prevented by oncogenic mutations in tetramerization domain

Nucleo-cytoplasmic environment modulates spatiotemporal p53 phase separation

Oncogenic Phase Transitions: How Mutant p53 Drives Amyloid Formation in p63 and p73 Liquid Droplets

Mechanistic Insight into the Destabilization of P53td Tetramer by Cancer-Related R337H Mutation: a Molecular Dynamics Study.

Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant P53 Promotes Transactivation-Independent Mitochondrial Cell Death.

Abstract LB361: Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant P53 Promotes Transactivation-Independent Mitochondrial Cell Death

Conformational Stability and Dynamics of the Cancer‐associated Isoform Δ133p53β Are Modulated by P53 Peptides and P53‐specific DNA

Microsecond Molecular Dynamics Simulations Reveal the Allosteric Regulatory Mechanism of P53 R249S Mutation in P53-Associated Liver Cancer

Self-Aggregation And Coaggregation Of The P53 Core Fragment With Its Aggregation Gatekeeper Variant

Multi-scale in silico analysis of the phase separation behavior of FUS mutants

Multisite Aggregation Of P53 And Implications For Drug Rescue

Uncovering Intermolecular Interactions Driving the Liquid-Liquid Phase Separation of the TDP-43 Low-Complexity Domain via Atomistic Dimerization Simulations

Phase separation of 53BP1 determines liquid-like behavior of DNA repair compartments

Insights into Allosteric Mechanisms of the Lung-Enriched P53 Mutants V157F and R158L.

Gain of Function of Mutant P53 by Coaggregation with Multiple Tumor Suppressors

Insights into the Atomistic Mechanisms of Phosphorylation in Disrupting Liquid-Liquid Phase Separation and Aggregation of the FUS Low-Complexity Domain

Molecular insights into TP53 mutation (p. Arg267Trp) and its connection to Choroid Plexus Carcinomas and Li-Fraumeni Syndrome

Oncogenic p53 triggers amyloid aggregation of p63 and p73 liquid droplets

Phosphorylation and specific DNA improved the incorporation ability of p53 into functional condensates

The Function of a Heterozygous P53 Mutation in a Li-Fraumeni Syndrome Patient.